These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21402292)

  • 41. Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: discrete choice experiment.
    Kessler TM; Maric A; Mordasini L; Wöllner J; Pannek J; Mehnert U; van Kerrebroeck PE; Bachmann LM
    Neurourol Urodyn; 2014 Nov; 33(8):1240-6. PubMed ID: 24127359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sacral neuromodulation system for treating refractory overactive bladder.
    Phillips A
    Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of sacral neuromodulation for chronic refractory constipation in children and adolescents: a Markov model analysis.
    van der Wilt AA; Groenewoud HHM; Benninga MA; Dirksen CD; Baeten CGMI; Bouvy ND; Melenhorst J; Breukink SO
    Colorectal Dis; 2017 Nov; 19(11):1013-1023. PubMed ID: 28834055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuromodulation for intractable OAB.
    Apostolidis A
    Neurourol Urodyn; 2011 Jun; 30(5):766-70. PubMed ID: 21661027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of test phase implantation strategies for InterStim® sacral neuromodulation.
    Kantartzis KL; Shepherd JP
    Female Pelvic Med Reconstr Surg; 2013; 19(6):322-7. PubMed ID: 24165444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.
    Heemskerk SCM; Rotteveel AH; Benninga MA; Baeten CIM; Masclee AAM; Melenhorst J; van Kuijk SMJ; Dirksen CD; Breukink SO
    Int J Colorectal Dis; 2018 Apr; 33(4):493-501. PubMed ID: 29470731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe.
    Ruff L; Bagshaw E; Aracil J; Velard ME; Pardhanani G; Hepp Z
    J Med Econ; 2016 Dec; 19(12):1107-1115. PubMed ID: 27266958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
    Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
    Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
    Zahner PM; Giusto LL; Goldman HB
    Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using electroacupuncture with optimized acupoint positioning to predict the efficacy of sacral neuromodulation of refractory overactive bladder: A case report.
    Shen J; Luo R; Zhang L; Li Y; Ke L; Gao Z
    Medicine (Baltimore); 2019 Nov; 98(45):e17795. PubMed ID: 31702631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.